Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28874073 | 0.95 | TSHR (0.40) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL2038241 | 0.94 | TSHR (0.46) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL2034320 | 0.89 | TSHR (0.47) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL3677974 | 0.87 | TSHR (0.42) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL28874076 | 0.85 | TSHR (0.41) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL20582579 | 0.84 | THRB (0.40) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL28874094 | 0.84 | TSHR (0.43) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL2040421 | 0.84 | TSHR (0.47) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL28874092 | 0.84 | TSHR (0.46) | TSHRTHRBLPAR3LPAR1LPAR2 | |
| SCHEMBL2036641 | 0.83 | THRB (0.39) | TSHRTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130034509-A1 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU | L'OREAL (FR) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034509-A1 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU | POLR1C, CUTA, MITF | TSHR 3797/4885THRB 4619/4885LPAR3 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.